Laurence Cooper

Laurence Cooper has over 20 years of experience in the medical and scientific field. From 1999 to 2001, they were an Instructor at the Fred Hutchinson Cancer Research Center, where they completed a Fellowship in pediatric oncology and bone marrow transplantation, as well as a Research Fellowship on the genetic engineering of T cells. From 2001 to 2005, they were an Assistant Professor at the City of Hope. From 2005 to 2015, they were a Professor and Chief of Pediatric Bone Marrow Transplantation at the MD Anderson Cancer Center. In 2015, they became the Chief Executive Officer of Ziopharm Oncology, where they grew the company to approximately 100 employees and established a joint venture (Eden BioCell) in Asia for CAR-T. In 2019, they became the Director of Secure Transfusion Solutions. In 2020, they became the Co-Founder of Auravax Theurapeutics, Inc., and also founded their own company, Dr Laurence Cooper. In 2021, they became an Advisor for Alaunos (Ziopharm) Oncology, and in 2022, they became the Chairman of the Board for Bio4t2.

Laurence Cooper obtained their Doctor of Medicine (MD) and Doctor of Philosophy (PhD) degrees from Case Western Reserve University in 1994 and 1993 respectively, with a field of study in Medicine and Immunology respectively. Laurence also obtained a Bachelor of Arts (BA) degree from Kenyon College in 1986, with a field of study in Biology, General. Additionally, they obtained certifications in Pediatric Hematology-Oncology from the American Board of Pediatrics (ABP) in April 2013, and General Pediatrics from the same institution in October 1999.